渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BIIB 渤健公司

休市中 02-13 16:00:00 EST

196.52

+1.02

+0.52%

盘后196.50

-0.02-0.01%

19:59 EST

最高199.50	最低195.52	成交量135.28万
今开196.27	昨收195.50	日振幅2.04%
总市值288.30亿	流通市值287.36亿	总股本1.47亿
成交额2.67亿	换手率0.93%	流通股本1.46亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BIIB","market":"US","secType":"STK","nameCN":"渤健公司","latestPrice":196.52,"timestamp":1771016400000,"preClose":195.5,"halted":0,"volume":1352790,"hourTrading":{"tag":"盘后","latestPrice":196.5,"preClose":196.52,"latestTime":"19:59 EST","volume":53616,"amount":10536701.99,"timestamp":1771030781030,"change":-0.02,"changeRate":-0.000102,"amplitude":0.000102},"delay":0,"changeRate":0.0052173913043478785,"floatShares":146226846,"shares":146702272,"eps":8.79,"marketStatus":"休市中","change":1.02,"latestTime":"02-13 16:00:00 EST","open":196.27,"high":199.4999,"low":195.52,"amount":266620948.2072,"amplitude":0.020358,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":8.79,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":685080000000,"exchange":"NASDAQ","adjPreClose":195.5,"preHourTrading":{"tag":"盘前","latestPrice":196.6,"preClose":195.5,"latestTime":"09:28 EST","volume":371,"amount":72793.52045,"timestamp":1770992880002,"change":1.1,"changeRate":0.005627,"amplitude":0.038772},"postHourTrading":{"tag":"盘后","latestPrice":196.5,"preClose":196.52,"latestTime":"19:59 EST","volume":53616,"amount":10536701.99,"timestamp":1771030781030,"change":-0.02,"changeRate":-0.000102,"amplitude":0.000102},"volumeRatio":0.6769559470306166,"impliedVol":0.3382,"impliedVolPercentile":0.259},"requestUrl":"/m/hq/s/BIIB","defaultTab":"news","newsList":[{"id":"2609529234","title":"2025Q4| Vumerity逆势增长，Biogen销售额下滑好于分析师预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2609529234","media":"Minhua笔记","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609529234?lang=zh_cn&edition=full","pubTime":"2026-02-07 15:54","pubTimestamp":1770450891,"startTime":"0","endTime":"0","summary":"2月6日，渤健公布2025年第四季度及全年业绩，整体销售额下滑7%至23亿美元，下滑主要因多发性硬化症  Tecfidera面临仿制药竞争后销售额暴跌51%。尽管Biogen预计其 2026 年的盈利预测将超出分析师预期，但该公司仍表示，由于其大部分 MS 产品持续面临压力，销售额将出现中等个位数的下滑。然而，Vumerity有望成为例外。2025年第四季度，Biogen整体销售额下滑7%至23亿美元，但高于分析师预测的22亿美元。Biogen寄希望于其在研产品线能够重回销售增长轨道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020715590995403dde&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020715590995403dde&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0234570918.USD","LU1244550221.USD","LU2023251221.USD","LU0225283273.USD","BK4585","LU1989772923.USD","LU0314104364.USD","LU0528227936.USD","LU0267386448.USD","BK4581","LU1720051017.SGD","BK4127","IE00BZ1G4Q59.USD","LU0106261372.USD","LU2089284900.SGD","LU0889565916.HKD","LU0557290698.USD","LU0320765646.SGD","LU0158827948.USD","LU1668664300.SGD","LU2089283258.USD","LU0795875169.SGD","LU0882574139.USD","LU1791710400.SGD","LU0320765992.SGD","LU1363072403.SGD","IE00BKVL7J92.USD","IE00B19Z9P08.USD","LU2133065610.SGD","LU0971096721.USD","IE00B19Z9Z06.USD","LU1244550494.USD","LU1244550577.SGD","LU1732800096.USD","BK4504","LU0795875086.SGD","LU2271345857.HKD","LU0098860793.USD","LU1791710582.SGD","BK4534","IE00B894F039.SGD","LU0006306889.USD","LU1074936037.SGD","LU2111349929.HKD","LU0158827781.USD","BK4588","BIIB","BK4139","LU2028103732.USD","BK4516"],"gpt_icon":0},{"id":"2609597324","title":"渤健公司(BIIB)升4.34% 第四季业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2609597324","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609597324?lang=zh_cn&edition=full","pubTime":"2026-02-06 23:27","pubTimestamp":1770391629,"startTime":"0","endTime":"0","summary":"金吾财讯 | 渤健公司(BIIB)震荡扬升，截至发稿，升4.34%，报193.4美元。公司公布，去年第四季录每股盈利为1.99美元，高于之前预期的1.59美元；总营收23亿美元，亦高于预期的22亿美元。业绩指引方面，公司预计今年调整后每股盈利为15.25美元至16.25美元，高于市场预期的14.92美元。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/Mjg1NzQ1OGJhMDJiZWVjMjcxYjFlYjJjMTY3ODIxNTA4Njc=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/Mjg1NzQ1OGJhMDJiZWVjMjcxYjFlYjJjMTY3ODIxNTA4Njc=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"296982","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","IE00B19Z9Z06.USD","BK4139","IE00B19Z9P08.USD","LU0889565916.HKD","BIIB","LU0234570918.USD","BK4585","LU0109394709.USD","IE00B894F039.SGD","LU0320765992.SGD","BK4588","BK4533"],"gpt_icon":0},{"id":"1198005801","title":"异动解读 | 渤健公司盘中大涨5.13%，因年度利润超预期且展望积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1198005801","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198005801?lang=zh_cn&edition=full","pubTime":"2026-02-06 22:59","pubTimestamp":1770389971,"startTime":"0","endTime":"0","summary":"渤健公司(BIIB)今日盘中大涨5.13%，引起了市场的广泛关注。消息面上，该公司公布的第四季度业绩及2026年利润展望均超出华尔街预期。其第四季度调整后每股收益为1.99美元，高于分析师平均预期的1.59美元；季度收入达23亿美元，亦高于预期。此外，公司预计2026年调整后每股利润将在15.25美元至16.25美元之间，高于市场预期的14.92美元。业绩超预期主要得益于其阿尔茨海默病治疗药物Leqembi等新药的需求增长，以及公司持续的成本削减措施。管理层表示，严格的费用纪律正在缓冲其多发性硬化症业务销售额下滑的影响，并对新药产品的增长抱有信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BIIB"],"gpt_icon":0},{"id":"1102477859","title":"渤健高管：公司将以最惠国视角推进欧洲新品上市 初期拟锁定三至四个国家","url":"https://stock-news.laohu8.com/highlight/detail?id=1102477859","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102477859?lang=zh_cn&edition=full","pubTime":"2026-02-06 22:48","pubTimestamp":1770389299,"startTime":"0","endTime":"0","summary":"渤健公司高管近日透露，在欧洲市场推出新产品时，公司将采用最惠国待遇原则作为战略导向。据悉，初期计划优先选择三到四个国家作为试点市场，通过精细化布局逐步拓展欧洲业务版图。这种分阶段推进的策略既有助于控制风险，又能根据市场反馈动态调整商业部署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","IE00B19Z9Z06.USD","IE00B894F039.SGD","BK4532","BK4588","IE00B19Z9P08.USD","LU0234570918.USD","LU0889565916.HKD","BK4585","BK4139","LU0109394709.USD","BK4533","LU0320765992.SGD"],"gpt_icon":0},{"id":"1133804934","title":"渤健CEO称Leqembi口服剂符合D部分报销资格，但全额报销需等到2027年1月1日","url":"https://stock-news.laohu8.com/highlight/detail?id=1133804934","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133804934?lang=zh_cn&edition=full","pubTime":"2026-02-06 21:45","pubTimestamp":1770385515,"startTime":"0","endTime":"0","summary":"渤健公司首席执行官在电话会议中透露，其阿尔茨海默病治疗药物Leqembi的口服剂型已获得医疗保险D部分报销资格。不过，该药物要实现全额报销，必须等到2027年1月1日。\n这一时间表的设定，反映出医疗保险体系对新药报销审批流程的复杂性。虽然Leqembi口服剂已迈出关键一步，但患者要享受完整报销福利还需等待三年过渡期。\n此次披露的报销时间线，对渤健公司的市场战略和患者用药可及性都将产生深远影响。医药行业分析师指出，这一安排既体现了监管审慎，也为医疗支付体系适应创新疗法留出缓冲空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00B19Z9P08.USD","LU0320765992.SGD","LU0889565916.HKD","BK4588","IE00B19Z9Z06.USD","BK4532","LU0234570918.USD","LU0109394709.USD","BK4139","BIIB","BK4533","IE00B894F039.SGD"],"gpt_icon":0},{"id":"2609859369","title":"“瘦身术”砍成本+押注阿尔茨海默病药等新药产品线 百健(BIIB.US)利润展望强于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2609859369","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609859369?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:33","pubTimestamp":1770381227,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百健公司于2月6日美股盘前公布2025年第四季度业绩以及未来业绩展望区间，最新数据显示，管理层给出的2026年利润展望高于华尔街分析师平均预期，这表明大幅削减成本的举措正在缓冲其多发性硬化症业务销售额萎缩带来的影响。过去12个月其股价已大幅上涨30%。维布拉赫表示，更广泛地使用血液检测来诊断阿尔茨海默病，也可能有助于扩大符合治疗条件的老年患者群体。美国监管机构的正式决定预计将在4月作出。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B894F039.SGD","LU0889565916.HKD","LU0234570918.USD","BK4532","BK4585","BK4139","IE00B19Z9P08.USD","BK4533","LU0320765992.SGD","BIIB","BK4588","IE00B19Z9Z06.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"1164132348","title":"FDA优先审评受理Leqembi®（Lecanemab-Irmb）皮下起始剂量补充生物制剂许可申请，用于早期阿尔茨海默病治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1164132348","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164132348?lang=zh_cn&edition=full","pubTime":"2026-01-26 07:30","pubTimestamp":1769383838,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式受理渤健公司旗下Leqembi®（Lecanemab-Irmb）的补充生物制剂许可申请，将其皮下注射起始剂量方案纳入优先审评通道，用于治疗早期阿尔茨海默病。此次审评聚焦于该疗法在给药方式上的创新突破，有望为患者提供更便捷的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9P08.USD","BIIB","BK4533","LU0109394709.USD","BK4588","IE00B894F039.SGD","BK4585","BK4139","BK4532","LU0320765992.SGD","LU0889565916.HKD","IE00B19Z9Z06.USD","LU0234570918.USD"],"gpt_icon":0},{"id":"2603608825","title":"高盛：Leqembi与研发管线支撑增收增利结构性变革，给予百健(BIIB.US)“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2603608825","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603608825?lang=zh_cn&edition=full","pubTime":"2026-01-15 17:10","pubTimestamp":1768468236,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛在与百健管理层会面后，给予其“买入”评级，目标价225美元。高盛表示，百健管理层强调了公司文化向专注于研发和费用控制的转变，这是其战略的一部分，旨在抵消多发性硬化症业务的下滑并推动增长。总而言之，高盛认为百健今年有望迎来转折点，这得益于研发管线催化剂和Leqembi的推动，以及严格的成本控制和优先发展早期罕见病和/或免疫学资产的合理业务发展策略。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"高盛：Leqembi与研发管线支撑增收增利结构性变革，给予百健(BIIB.US)“买入”评级","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BIIB"],"gpt_icon":0},{"id":"1133463005","title":"渤健公司预计第四季度支出2.22亿美元 每股盈利将受1.26美元冲击 股价应声下跌6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1133463005","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133463005?lang=zh_cn&edition=full","pubTime":"2026-01-14 23:24","pubTimestamp":1768404264,"startTime":"0","endTime":"0","summary":"渤健公司股价大幅下挫6%，此前该公司宣布预计第四季度将产生2.22亿美元的特殊支出。这笔一次性费用预计将使每股收益减少1.26美元，对当季盈利能力构成显著压力。\n市场对此消息反应迅速，投资者纷纷抛售股票，导致股价出现明显波动。此次支出预计将直接影响公司第四季度的财务表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","BK4139","BK4533","IE00B19Z9Z06.USD","LU0109394709.USD","IE00B894F039.SGD","BK4588","LU0234570918.USD","LU0320765992.SGD","BK4532","BK4585","LU0889565916.HKD","IE00B19Z9P08.USD"],"gpt_icon":0},{"id":"2603619522","title":"百健CEO：居家阿尔茨海默症药物具备超越礼来竞争疗法的优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2603619522","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603619522?lang=zh_cn&edition=full","pubTime":"2026-01-14 21:28","pubTimestamp":1768397307,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00B7KXQ091.USD","LU1093756168.USD","LU2357305700.SGD","IE00BJJMRZ35.SGD","LU2471134796.USD","BK4599","IE00BFSS7M15.SGD","LU0820561909.HKD","LU1551013342.USD","LU2456880835.USD","LU0203202063.USD","LU1868837300.USD","LU1868837136.USD","SG9999018857.SGD","LU0316494557.USD","LU2023250504.SGD","IE00BJLML261.HKD","LU0114720955.EUR","LU2089984988.USD","LU0943347566.SGD","LU0823434583.USD","IE00B1BXHZ80.USD","LU0256863811.USD","LU0456855351.SGD","IE00BWXC8680.SGD","LU0471298777.SGD","LU2237443465.HKD","LU0689472784.USD","LU2750360641.GBP","LU2112291526.USD","LU1232071149.USD","LU2265009873.SGD","LU0353189763.USD","LU2237443978.SGD","LU0320765059.SGD","LU1023059063.AUD","LU0094547139.USD","BK4581","LU0466842654.USD","LU0234572021.USD","IE00BN29S564.USD","LU2168563687.JPY","LU1093756325.SGD","LU0882574139.USD","IE00B4JS1V06.HKD","IE0009355771.USD","LU0708995401.HKD","LU2236285917.USD","LU2491050071.SGD","SG9999014898.SGD","SG9999015945.SGD","LU2168564149.EUR","LU0672654240.SGD","LU1323610961.USD","LU0097036916.USD","SGXZ31699556.SGD","LU1712237335.SGD","LU2417539215.USD","LU2468319806.SGD","LU1061106388.HKD","SG9999017495.SGD","BK4534","LU1291159041.SGD","LU1974910355.USD","LU2471134952.CNY","LU2361045086.USD","LU2462157665.USD","SG9999015952.SGD","IE00B4R5TH58.HKD","LU0109391861.USD","LU2264538146.SGD","BIIB","BK4007","LU1551013425.SGD","LU0786609619.USD","IE00BJT1NW94.SGD","LU2063271972.USD","LU2237438978.USD","IE00BFTCPJ56.SGD","SG9999018865.SGD","IE0002141913.USD","LU1127390331.HKD","GB00BDT5M118.USD","IE00B2B36J28.USD","IE00B775H168.HKD","LU2168564065.EUR","LU2237443895.HKD","LU2168564495.EUR","LU2750360997.AUD","IE00BKDWB100.SGD","LU0882574055.USD","LU2552382058.USD","LU0640476718.USD","LU0683600562.USD","LU0471298694.HKD","LU2108987350.USD","BK4533","LU2461242641.AUD","LLY","LU1623119135.USD","LU2746668461.USD","SG9999014914.USD","LU2471134879.HKD","LU2360106947.USD","LU2168564222.USD","LU0787776722.HKD","IE00BJJMRX11.SGD","LU0320765992.SGD","IE0004445015.USD","LU0823416689.USD","LU1720051108.HKD","LU0198837287.USD","LU1366192091.USD","SG9999015986.USD","LU0122379950.USD","LU2324357040.USD","SG9999001176.USD","LU0266013472.USD","SG9999015978.USD","LU0820561818.USD","LU1868836914.USD","LU0889565916.HKD","LU2361044949.HKD","LU1064131342.USD","LU1069344957.HKD","LU2237443622.USD","SG9999013999.USD","SGXZ99366536.SGD","LU2106854487.HKD","IE00BK4W5L77.USD","LU2746668974.SGD","LU2491050154.USD","LU1267930730.SGD","LU1988902786.USD","LU0385154629.USD","LU0061475181.USD","LU0323591593.USD","LU0823434740.USD","LU2602419157.SGD","SGXZ57979304.SGD","LU1814569148.SGD","LU0106261372.USD","LU2471134523.USD","LU0225283273.USD","LU0058720904.USD","LU1280957306.USD","LU0432979614.USD","BK4585","LU2087625088.SGD","LU2237443382.USD","LU2237443549.SGD","IE00BK4W5M84.HKD","LU0203201768.USD","LU2211815571.USD","LU1057294990.SGD","LU1804176565.USD","LU0006306889.USD","LU1868836591.USD","LU1720051017.SGD","SG9999014906.USD","LU0289739699.SGD","LU1989771016.USD","SG9999014880.SGD","SG9999001176.SGD","LU1035775433.USD","LU0354030438.USD","LU1548497426.USD","IE00BJJMRY28.SGD","IE0005OL40V9.USD","LU2491049909.HKD","LU1983299246.USD","LU2552382215.SGD","LU2361044865.SGD","LU0109394709.USD","LU0256863902.USD","LU1917777945.USD","SGXZ51526630.SGD","LU0354030511.USD","LU0079474960.USD","BK4516","LU0353189680.USD","LU0238689110.USD","LU2552382132.HKD","IE0004445239.USD","LU1868836757.USD","LU0096364046.USD","SGXZ81514606.USD","IE00BKPKM429.USD","LU0417517546.SGD","BK4588","IE00BFSS8Q28.SGD","IE00B1XK9C88.USD"],"gpt_icon":0},{"id":"2603514619","title":"百健(BIIB.US)押注家用阿尔茨海默病药物 称将成对抗礼来(LLY.US)的“制胜筹码”","url":"https://stock-news.laohu8.com/highlight/detail?id=2603514619","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603514619?lang=zh_cn&edition=full","pubTime":"2026-01-14 21:24","pubTimestamp":1768397046,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，在阿尔茨海默病新药市场竞争白热化之际，百健公司首席执行官克里斯·维巴赫近日表示，其与卫材合作开发的Leqembi家用注射剂型将成为公司对抗竞争对手礼来同类疗法的“关键优势”。相比之下，礼来的药物目前尚未提供家用给药选择。温和增长百健的投资者正密切关注Leqembi的市场推广情况。百健预计将于2028年公布该试验的结果。维巴赫说，“这几乎无疑是阿尔茨海默病治疗的未来方向。”","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1127390331.HKD","LU2168564065.EUR","LU0079474960.USD","LU0225283273.USD","LU0006306889.USD","SGXZ81514606.USD","BK4588","LU0820561909.HKD","LU2361045086.USD","SG9999013999.USD","LU0203201768.USD","IE00BN29S564.USD","LU0256863902.USD","BK4516","LU0640476718.USD","SG9999017495.SGD","LU1323610961.USD","BK4007","LU0122379950.USD","SG9999001176.SGD","LU1232071149.USD","SGXZ57979304.SGD","LU0943347566.SGD","LU0354030438.USD","IE0002141913.USD","SG9999014898.SGD","LU0689472784.USD","SG9999015986.USD","IE00BJLML261.HKD","LU2552382058.USD","LU0823416689.USD","LU0823434583.USD","LU1974910355.USD","LU1548497426.USD","LU1366192091.USD","SGXZ31699556.SGD","IE00B1BXHZ80.USD","LU0353189680.USD","LU2236285917.USD","LU2023250504.SGD","BIIB","BK4581","BK4533","LU2471134879.HKD","LU2211815571.USD","LU0456855351.SGD","LU0289739699.SGD","BK4139","IE00B894F039.SGD","LU2168564495.EUR","LU2552382132.HKD","LU1069344957.HKD","IE00B19Z9P08.USD","LU0354030511.USD","LU1035775433.USD","BK4534","LU1551013425.SGD","LU1988902786.USD","LU0882574139.USD","LU2471134952.CNY","LU2237443465.HKD","LU0708995401.HKD","IE0005OL40V9.USD","LU0417517546.SGD","LU2237443549.SGD","LU2360106947.USD","IE0004445015.USD","LU0203202063.USD","LU0385154629.USD","LU0238689110.USD","LU0786609619.USD","LU2237443382.USD","LU0471298694.HKD","SG9999015978.USD","LU0823434740.USD","LU2357305700.SGD","SG9999018865.SGD","LU2112291526.USD","IE0009355771.USD","IE0004445239.USD","LU0234572021.USD","LU0114720955.EUR","LU2750360997.AUD","LU1093756325.SGD","LU2265009873.SGD","LU0097036916.USD","SG9999014880.SGD","IE00BKDWB100.SGD","LU0323591593.USD","LU1280957306.USD","LU2491049909.HKD","LU1720051017.SGD","LU1057294990.SGD","LU1623119135.USD","SG9999018857.SGD","LU0109394709.USD","IE00BJT1NW94.SGD","SG9999014914.USD","LU2456880835.USD","LU0889565916.HKD","LU2237438978.USD","LU2168563687.JPY","LU0094547139.USD","IE00B1XK9C88.USD","LU2264538146.SGD","BK4599","LU0096364046.USD","LLY","LU1267930730.SGD","LU1023059063.AUD","LU2746668461.USD","LU2471134796.USD","LU1814569148.SGD","IE00BJJMRX11.SGD","LU2324357040.USD","LU2361044865.SGD","IE00BK4W5L77.USD","LU1804176565.USD","LU0234570918.USD","LU1551013342.USD","LU0320765992.SGD","LU0106261372.USD","IE00BFTCPJ56.SGD","IE00B19Z9Z06.USD","LU0109391861.USD","LU0256863811.USD","LU0672654240.SGD","LU0882574055.USD","LU0061475181.USD","LU1868837300.USD","SG9999001176.USD","IE00BWXC8680.SGD","LU2462157665.USD","LU1917777945.USD","LU2168564149.EUR","LU0198837287.USD","LU2106854487.HKD","LU0683600562.USD","SGXZ99366536.SGD","IE00BK4W5M84.HKD","LU1064131342.USD","LU1868836591.USD","SG9999014906.USD","LU2063271972.USD","IE00BJJMRZ35.SGD","LU1868837136.USD","IE00B4JS1V06.HKD","SG9999015952.SGD","LU1291159041.SGD","LU2237443895.HKD","LU1983299246.USD","LU1989771016.USD","LU2237443622.USD","LU2461242641.AUD","LU0466842654.USD","IE00B4R5TH58.HKD","LU2417539215.USD","LU2087625088.SGD","LU2746668974.SGD","LU1720051108.HKD","LU2602419157.SGD","IE00B2B36J28.USD","IE00B7KXQ091.USD","LU0353189763.USD","LU2491050071.SGD","LU1868836757.USD","IE00BFSS7M15.SGD","IE00BJJMRY28.SGD","SGXZ51526630.SGD","LU2168564222.USD","LU0266013472.USD","LU2108987350.USD","IE00B775H168.HKD","LU2237443978.SGD","GB00BDT5M118.USD","LU2552382215.SGD","LU0320765059.SGD","LU2750360641.GBP","LU2471134523.USD","BK4532","LU0471298777.SGD","LU2361044949.HKD","IE00BKPKM429.USD","LU1093756168.USD","LU0787776722.HKD","LU1868836914.USD","BK4585","LU0316494557.USD","LU2468319806.SGD","LU2089984988.USD","LU2491050154.USD","IE00BFSS8Q28.SGD","LU1712237335.SGD","LU0058720904.USD","LU1061106388.HKD","SG9999015945.SGD","LU0820561818.USD","LU0432979614.USD"],"gpt_icon":1},{"id":"1145314898","title":"渤健公司获欧盟委员会批准Spiranza®高剂量方案用于脊髓性肌萎缩症治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1145314898","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145314898?lang=zh_cn&edition=full","pubTime":"2026-01-13 00:11","pubTimestamp":1768234293,"startTime":"0","endTime":"0","summary":"欧盟委员会已正式批准渤健公司针对脊髓性肌萎缩症的Spiranza®（Nusinersen）高剂量治疗方案。这一监管里程碑标志着该疗法在欧盟市场获得重要拓展，为患者群体提供更具灵活性的用药选择。\n此次获批的高剂量方案将进一步提升药物在临床实践中的应用价值，凸显渤健公司在神经科学治疗领域持续创新的战略布局。监管机构的认可也为该疗法在更广泛患者群体中的使用铺平道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIIB","BK4588","IE00B19Z9P08.USD","BK4532","LU0889565916.HKD","IONS","LU0320765992.SGD","IE00B894F039.SGD","IE00B19Z9Z06.USD","BK4533","LU0109394709.USD","LU0234570918.USD","BK4585"],"gpt_icon":0},{"id":"1190397083","title":"美国官员称与安进、施贵宝、罗氏旗下基因泰克、吉利德、葛兰素史克、默沙东、诺华、赛诺菲和博瑞诺的交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1190397083","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190397083?lang=zh_cn&edition=full","pubTime":"2025-12-20 03:22","pubTimestamp":1766172127,"startTime":"0","endTime":"0","summary":"美国官员称与安进、施贵宝、罗氏旗下基因泰克、吉利德、葛兰素史克、默沙东、诺华、赛诺菲和博瑞诺的交易","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1481600234.SGD","LU0098860793.USD","IE00BJJMRZ35.SGD","BK4534","LU0477156953.USD","LU1015430645.USD","LU1057294990.SGD","BK4568","LU0575583348.USD","LU0971552830.HKD","LU0114720955.EUR","LU2361044949.HKD","IE00BWDBJ516.SGD","LU0965509101.SGD","LU1989771016.USD","BK4550","IE00B1BXHZ80.USD","IE00B2B36J28.USD","LU1400636491.USD","IE00BFTCPJ56.SGD","LU0965509283.SGD","IE000M9KFDE8.USD","LU0965508806.USD","LU2324357040.USD","LU0868494617.USD","LU0109981661.USD","LU1074936037.SGD","IE00BBT3K403.USD","LU0267386448.USD","LU2087621335.USD","LU1699723380.USD","BK4585","SG9999015952.SGD","LU0208291251.USD","LU0237698245.USD","LU0545562505.USD","SG9999002232.USD","BK5011","LU1481599808.USD","SG9999014567.USD","LU2242646821.SGD","LU0225771236.USD","IE00BFXG1179.USD","LU0225284248.USD","LU1228905540.USD","LU1674673691.USD","LU1934455863.HKD","LU0965509010.AUD","LU1645745479.HKD","IE00B19Z3581.USD","LU1035777561.USD","LU1868837136.USD","LU1989772840.SGD","RHHBY","LU0096364046.USD","SGXZ57979304.SGD","LU1032466523.USD","IE00BZ1G4Q59.USD","LU1934455194.USD","LU2360032135.SGD","BK4566","IE00BKVL7J92.USD","LU0234572021.USD","LU1430594728.SGD","04332","NVS","LU0823416689.USD","LU1061106388.HKD","LU1983299246.USD","LU1035773651.USD","IE0002141913.USD","LU1868836914.USD","LU1066051225.USD","LU0985481810.HKD","SG9999013999.USD","LU1037948897.HKD","IE00BQJZX424.USD","BIIB","LU1066053197.SGD","BMY","LU1929549753.HKD","LU2112291526.USD","BK4578","IE00BSNM7G36.USD","LU0980610538.SGD","LU2125154778.USD","LU2361044865.SGD","LU0321505868.SGD","LU1037948541.HKD","LU1069347547.HKD","LU0265550359.USD","LU1585245621.USD","LU1670711040.USD","IE00B4R5TH58.HKD","LU1228905037.USD","LU1974910355.USD","LU0648001328.SGD","LU1261432733.SGD","LU1202635105.USD","SG9999014575.USD","LU1116320737.USD","SG9999014559.SGD","LU0266013472.USD","IE00BLSP4239.USD","LU2133065610.SGD","LU0320765646.SGD","LU0161305163.EUR","BK4588","LU1868836757.USD","LU1670711123.USD","LU1674673428.USD","LU0130517989.USD","LU0882574055.USD","LU1778281490.HKD","BK4139","IE0034235071.USD","LU1571399168.USD","SG9999001176.USD","IE00B7SZLL34.SGD","LU2023250504.SGD","LU0234570918.USD","GILD","LU0061475181.USD","SG9999015945.SGD","LU0211331839.USD","LU1093756325.SGD","LU1046248800.SGD","LU2361045086.USD","BK4007","IE0002270589.USD","LU1116320901.HKD","LU0265550946.USD","LU1066051498.USD","LU1670756490.USD","LU2089984988.USD","LU1941712264.USD","LU0320765489.SGD","LU0456855351.SGD","MRK","IE00B3T34201.USD","SG9999002224.SGD","LU2468319806.SGD","SG9999014542.SGD","LU0861579265.USD","LU1309081286.SGD","LU1066051811.HKD","LU1670710661.SGD","LU1868837300.USD","BK4532","LU1941712348.USD","LU0109394709.USD","LU0203345920.USD","LU1023059063.AUD","LU1400636657.SGD","LU1868836591.USD","LU2125154935.USD","LU0122379950.USD","SG9999001440.SGD","BK4533","LU0203347892.USD","LU1098665638.USD","SNY","LU0238689110.USD","GSK","LU0889565916.HKD","LU1400636574.HKD","SG9999015341.SGD","BK4581","LU0321505439.SGD","LU1839511570.USD","LU0289739699.SGD","LU0320765992.SGD","BK4599","LU1162221912.USD","LU0070302665.USD","LU0106261372.USD","LU1291159041.SGD","LU0306807586.USD","LU0971552673.USD","SG9999015358.SGD","LU0006306889.USD","IE00B19Z3B42.SGD","LU2023250843.SGD","SG9999001176.SGD","LU1670710588.SGD","LU1718418525.SGD","LU1323610961.USD","LU2242652126.USD","LU1934455277.USD","IE0009355771.USD","LU1064927863.SGD","LU1093756168.USD","LU2106854487.HKD","SG9999015978.USD","IE00BN8TJ469.HKD","LU2461242641.AUD","LU1487256676.USD","AMGN","LU0130102774.USD","BK4583","LU1302929846.USD","BK4516","LU1917777945.USD","LU0058720904.USD","LU0985320562.USD","LU1989772923.USD","SG9999015986.USD","IE00BLSP4452.SGD","LU1201861249.SGD","LU0306806265.USD","IE00BJT1NW94.SGD","BK4559"],"gpt_icon":0},{"id":"1166333259","title":"纳斯达克宣布渤健、CDW Corporation、GLOBALFOUNDRIES、lululemon athletica、安森美半导体、Trade Desk 将退出纳斯达克100指数","url":"https://stock-news.laohu8.com/highlight/detail?id=1166333259","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166333259?lang=zh_cn&edition=full","pubTime":"2025-12-13 09:21","pubTimestamp":1765588891,"startTime":"0","endTime":"0","summary":"12月12日（路透社）- 纳斯达克公司宣布：*纳斯达克公司 - 宣布纳斯达克100指数的重组，将于12月22日生效* 纳斯达克公司：六家公司将被添加到纳斯达克100指数* 纳斯达克公司：渤健、CDW Corporation、GLOBALFOUNDRIES、lululemon athletica、安森美半导体、Trade Desk 将退出纳斯达克100指数* 纳斯达克公司：阿尔尼拉姆制药公司、FERROVIAL、INSMED、Monolithic Power Systems、希捷科技、西部数据将被添加到纳斯达克100指数。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"379c269ef09dde4ff2ea787d7ec186f0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203347892.USD","IE00B19Z9Z06.USD","LU1235294995.USD","LU1548497426.USD","BK4141","LU0114720955.EUR","LU1992135472.HKD","IE00B894F039.SGD","LU1267930730.SGD","LU2360106780.USD","GFS","BK4512","LU0056508442.USD","LU1861214812.USD","LU0444973449.USD","LU0124384867.USD","IE00BZ199S13.USD","LU1815336760.USD","LU2322448791.USD","LU2473716301.USD","LU2272731782.SGD","LU2272731865.HKD","LU2298322129.HKD","LU0109391861.USD","IE00BN0W2T93.GBP","LU1720051017.SGD","BK4528","IE00BN0W2V16.EUR","TTD","LU2357305700.SGD","LU0823411888.USD","LU1861220033.SGD","LU1978683503.SGD","BK4170","LU0234570918.USD","WDC","LU0320765059.SGD","LU0957808578.USD","BK4139","BK4585","LU2272731600.USD","LU1035773651.USD","LU0109394709.USD","LU1069347547.HKD","BK4613","LU0708995401.HKD","LU0320765992.SGD","LU0476273544.USD","LU0724618433.USD","LU0353189763.USD","LU2087625088.SGD","LU1992135399.USD","BK4202","BIIB","LU0348723411.USD","CDW","LU1861219969.SGD","IE00BD6J9T35.USD","LU1496350502.SGD","IE00BN0W2W23.USD","LU0353189680.USD","ON","BK4588","LU2290526834.HKD","LU1861215975.USD","LU1720051108.HKD","LU0081259029.USD","LU2322448957.HKD","LU1046421795.USD","BK4605","LU2360107325.USD","MPWR","LU0444971666.USD","BK4548","LU0672654240.SGD","BK4532","LULU","LU2250418816.HKD","IE00BFMHRM44.USD","BK4533","LU1854104046.USD","BK4023","ALNY","IE00B19Z9P08.USD","LU1670627923.USD","LU0203345920.USD","BK4140","LU0006061336.USD","LU0274383776.USD","BK4009","LU1854103824.USD","LU1823568750.SGD","LU1670628061.USD","BK4504","LU2360107168.USD","LU1852331112.SGD","STX","LU2931357623.SGD","LU0882574055.USD","LU1642822529.SGD","LU0889565916.HKD","LU2089985449.USD"],"gpt_icon":0},{"id":"1117266784","title":"纳斯达克100指数调整：新增希捷科技等6家公司，剔除安森美半导体等6家公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1117266784","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117266784?lang=zh_cn&edition=full","pubTime":"2025-12-13 09:08","pubTimestamp":1765588106,"startTime":"0","endTime":"0","summary":"12月13日，纳斯达克公司宣布纳斯达克100指数成份股调整将于12月22日生效。6家公司即将被纳入纳斯达克100指数。分别是艾尼拉姆制药公司、费罗维亚集团、英斯梅德公司、单片电源系统公司、希捷科技控股有限公司和西部数据公司。而有6家被移出，百健公司（Biogen）CDW公司、格芯公司、露露乐蒙、安森美半导体和交易台公司（The Trade Desk）。","market":"us","thumbnail":"https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"379c269ef09dde4ff2ea787d7ec186f0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"纳斯达克100指数调整：新增希捷科技等6家公司，剔除安森美半导体等6家公司","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GFS","CDW","WDC","BIIB","LULU","STX","FER","ALNY","NDAQ","ON","MPWR","TTD"],"gpt_icon":0},{"id":"1141399315","title":"纳斯达克公司：渤健公司、CDW Corporation、GLOBALFOUNDRIES、lululemon athletica、安森美半导体及Trade Desk将被剔除出纳斯达克100指数","url":"https://stock-news.laohu8.com/highlight/detail?id=1141399315","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141399315?lang=zh_cn&edition=full","pubTime":"2025-12-13 09:04","pubTimestamp":1765587854,"startTime":"0","endTime":"0","summary":"纳斯达克公司：渤健公司、CDW Corporation、GLOBALFOUNDRIES、lululemon athletica、安森美半导体及Trade Desk将被剔除出纳斯达克100指数","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"379c269ef09dde4ff2ea787d7ec186f0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4528","LU1861215975.USD","LU2360107325.USD","BK4140","BK4532","LU0724618433.USD","BK4613","LU0320765992.SGD","IE00B19Z9P08.USD","LU0889565916.HKD","CDW","LU2095319765.USD","IE00BGHQF748.EUR","GFS","BIIB","BK4023","IE00BFMHRM44.USD","BK4504","SG9999014005.SGD","IE00BKPKM429.USD","BK4202","BK4141","BK4009","LU0823411888.USD","LU1861219969.SGD","LU1854103824.USD","LU1861214812.USD","BK4588","BK4112","IE00B64PRP62.GBP","LU1720051108.HKD","LU2357305700.SGD","SG9999014021.USD","LU1854104046.USD","LU1496350502.SGD","IE00B894F039.SGD","IE00B19Z9Z06.USD","ON","SG9999014039.USD","BK4512","LU2298322129.HKD","IE00BZ199S13.USD","LU0314104364.USD","LU1720051017.SGD","SG9999014013.SGD","BK4548","LULU","BK4605","LU2210149790.SGD","LU1861220033.SGD","LU1978683503.SGD","LU0109394709.USD","LU2210150020.SGD","IE00BD6J9T35.USD","LU0348723411.USD","BK4585","LU0124384867.USD","LU0234570918.USD","BK4139","LU1548497426.USD","NDAQ","TTD","IE00B3QW5Z07.USD","BK4533"],"gpt_icon":0},{"id":"1190730879","title":"渤健公司获得加拿大卫生部对Zurzuvae™（Zuranolone）的授权，成为加拿大唯一针对成人产后抑郁症的治疗方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1190730879","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190730879?lang=zh_cn&edition=full","pubTime":"2025-12-09 20:03","pubTimestamp":1765281816,"startTime":"0","endTime":"0","summary":"渤健公司获得加拿大卫生部对Zurzuvae™（Zuranolone）的授权，成为加拿大唯一针对成人产后抑郁症的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","IE00B894F039.SGD","BK4532","IE00B19Z9Z06.USD","BIIB","LU0889565916.HKD","BK4533","BK4139","LU0234570918.USD","LU0320765992.SGD","BK4585","BK4588","IE00B19Z9P08.USD"],"gpt_icon":0},{"id":"1149660254","title":"Stoke Therapeutics与渤健公司在2025年美国癫痫学会年会上展示进一步支持Zorevunersen作为Dravet综合症治疗药物的疾病改变潜力的数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1149660254","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149660254?lang=zh_cn&edition=full","pubTime":"2025-12-05 22:00","pubTimestamp":1764943218,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics与渤健公司在2025年美国癫痫学会年会上展示进一步支持Zorevunersen作为Dravet综合症治疗药物的疾病改变潜力的数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STOK","BK4532","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","BK4585","IE00B894F039.SGD","BK4588","LU0234570918.USD","BIIB","BK4533","LU0109394709.USD","BK4139","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"1166943636","title":"Eisai 在2025年阿尔茨海默病临床试验会议上展示 Leqembi®（Lecanemab-Irmb）在早期阿尔茨海默病持续和扩展益处的新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1166943636","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166943636?lang=zh_cn&edition=full","pubTime":"2025-12-04 07:11","pubTimestamp":1764803473,"startTime":"0","endTime":"0","summary":"Eisai 在2025年阿尔茨海默病临床试验会议上展示 Leqembi®（Lecanemab-Irmb）在早期阿尔茨海默病持续和扩展益处的新数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE00B894F039.SGD","IE00B19Z9Z06.USD","BIIB","LU0234570918.USD","BK4532","BK4588","BK4139","BK4585","LU0889565916.HKD","BK4533","IE00B19Z9P08.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"1183487643","title":"2025年阿尔茨海默病临床试验会议上公布的新数据确认Leqembi® (Lecanemab-Irmb)对脑脊液中神经毒性aβ原纤维的药理作用","url":"https://stock-news.laohu8.com/highlight/detail?id=1183487643","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183487643?lang=zh_cn&edition=full","pubTime":"2025-12-03 05:40","pubTimestamp":1764711612,"startTime":"0","endTime":"0","summary":"2025年阿尔茨海默病临床试验会议上公布的新数据确认Leqembi® (Lecanemab-Irmb)对脑脊液中神经毒性aβ原纤维的药理作用","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B894F039.SGD","BK4588","BK4532","BK4533","BIIB","LU0320765992.SGD","LU0109394709.USD","IE00B19Z9Z06.USD","BK4139","LU0889565916.HKD","LU0234570918.USD","BK4585","IE00B19Z9P08.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biogen.com;investors.biogen.com","stockEarnings":[{"period":"1week","weight":-0.0232},{"period":"1month","weight":0.1607},{"period":"3month","weight":0.1729},{"period":"6month","weight":0.4179},{"period":"1year","weight":0.4194},{"period":"ytd","weight":0.1167}],"compareEarnings":[{"period":"1week","weight":-0.0128},{"period":"1month","weight":-0.0125},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.0595},{"period":"1year","weight":0.1181},{"period":"ytd","weight":-0.0002}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biogen Inc.于1985年在加利福尼亚州以IDEC制药公司的名义成立，并于1997年重新注册为特拉华州公司。2003年，收购了Biogen, Inc.，并将公司名称更改为Biogen Idec Inc.。该公司是一家全球性生物制药公司，致力于为患有严重复杂疾病的人发现、开发和提供创新疗法。该公司拥有广泛的多发性硬化症（MS）药物组合，推出了首个获批治疗脊髓性肌萎缩症（SMA）的药物，共同开发了解决阿尔茨海默病定义病理学的治疗方法，并推出了首个获批的针对肌萎缩侧索硬化症（ALS）遗传原因的疗法。渤健还销售第一个也是唯一一个批准用于治疗16岁及以上成人和青少年的弗里德赖希共济失调（FA）的药物。其研发工作专注于神经病学、专业免疫学和罕见病，并得到内部项目、合作和收购的支持。该公司将生物制剂和生物仿制药商业化，并与领先的制药公司保持战略合作伙伴关系，以推进其产品组合。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.039226},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.002063},{"month":3,"riseRate":0.5,"avgChangeRate":-0.023281},{"month":4,"riseRate":0.323529,"avgChangeRate":-0.021192},{"month":5,"riseRate":0.617647,"avgChangeRate":0.03339},{"month":6,"riseRate":0.470588,"avgChangeRate":0.016596},{"month":7,"riseRate":0.676471,"avgChangeRate":0.034715},{"month":8,"riseRate":0.588235,"avgChangeRate":0.030673},{"month":9,"riseRate":0.5,"avgChangeRate":0.023197},{"month":10,"riseRate":0.542857,"avgChangeRate":0.058896},{"month":11,"riseRate":0.6,"avgChangeRate":0.018187},{"month":12,"riseRate":0.457143,"avgChangeRate":0.034185}],"exchange":"NASDAQ","name":"渤健公司","nameEN":"Biogen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"渤健公司,BIIB,渤健公司股票,渤健公司股票老虎,渤健公司股票老虎国际,渤健公司行情,渤健公司股票行情,渤健公司股价,渤健公司股市,渤健公司股票价格,渤健公司股票交易,渤健公司股票购买,渤健公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}